SANUWAVE Health, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed October 21, 2021. This is an annual report, not a standalone Q4 report. SANUWAVE develops and sells noninvasive wound-care and regenerative-medicine products. In August 2020, it acquired Celularity’s UltraMIST assets and obtained licenses to market Biovance and Interfyl biologic products.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $4.06 million | $1.03 million |
| Gross profit (margin) | $2.90 million (71%) | $0.49 million (48%) |
| Operating loss | $25.20 million | $8.79 million |
| Net loss | $30.94 million | $10.43 million |
| Cash used in operating activities | $12.72 million | $6.41 million |
- Revenue grew 294%, primarily following the UltraMIST acquisition. The filing attributes $3.68 million of revenue to UltraMIST after acquisition in its MD&A, while the acquisition note reports $3.63 million of UltraMIST revenue; verify the difference.
- Year-end cash was $2.44 million; current assets were $7.93 million against current liabilities of $36.17 million, a working-capital deficit of approximately $28.25 million. Total liabilities were $36.75 million, and stockholders’ deficit was $13.72 million.
- Cash used in investing was $20.05 million, principally the UltraMIST acquisition. Financing provided $33.45 million, including private-placement proceeds and senior secured debt.
- The balance sheet reported a $15 million senior secured note at $10.68 million carrying value, a $4 million Celularity seller note, and $1.60 million of related-party convertible notes, all identified as in default at year-end. Warrant liability was $8.86 million.
Material changes and unusual items
- The $24 million UltraMIST asset acquisition expanded the portfolio to include the UltraMIST wound-therapy system and licensed Biovance and Interfyl products. Acquisition-related selling and administrative costs contributed to higher expenses.
- A $7.19 million impairment charge was recorded in Q4 for the acquired biologics customer-relationship intangible, after sales materially missed acquisition projections; the company said it did not expect those sales to recover sufficiently.
- Selling and marketing expense rose to $5.16 million from $1.59 million; general and administrative expense increased to $13.72 million from $6.44 million. Other expense rose to $5.74 million, including warrant remeasurement, interest, and debt-extinguishment costs.
- Shares outstanding increased from 293.8 million at year-end 2019 to 470.7 million at year-end 2020, reflecting equity financings and other issuances. The filing reports 481.6 million shares outstanding as of October 11, 2021.
Outlook, risks, and contingencies
- Management stated that recurring losses and debt defaults raised substantial doubt about the company’s ability to continue as a going concern. The auditor’s opinion on the financial statements was unqualified but included a going-concern explanatory paragraph.
- Management estimated operating cash use of $0.5–$1.0 million per month in the first half of 2021, anticipated use of up to $100,000 per month in the second half, and targeted break-even in the first half of 2022. These are projections, not results reported for 2020.
- Management planned to seek capital through strategic partners, licensing, warrant exercises, equity, or debt; it warned that financing might not be available on expected terms and could significantly dilute shareholders. The filing reports $2.3 million raised in securities transactions closing in 2021.
- After year-end, the $4 million seller note and related-party notes of approximately $1.37 million and $224,000 matured unpaid in August 2021 and went into default. The senior secured lender’s minimum-liquidity default also remained unresolved.
- Celularity notified the company in May 2021 of alleged noncompliance with the Biovance license; SANUWAVE disputed the allegation and asserted supplier breaches. In September 2021, Minnetronix cancelled an UltraMIST production order after production delays and asserted $319,746 in cancellation fees; the company disputed aspects of the notice. Outcomes were uncertain.
- COVID-19 disrupted clinical-trial activity and could reduce procedures, sales, and supply availability. Other disclosed risks include limited reimbursement, competition, reliance on key suppliers, and potential financing and dilution needs.
- Disclosure controls and internal control over financial reporting were deemed ineffective at December 31, 2020, with material weaknesses involving technical accounting, controls design, and IT processes. The 10-K and the March and June 2021 Forms 10-Q were late; the company reported its stock had moved to the OTC Expert Market.
Important facts for investors to verify
- Current cash, operating cash burn, and progress toward management’s stated 2022 break-even target.
- Status, accrued interest, enforcement terms, and any resolutions of the defaulted senior and convertible notes; confirm the lender’s continuing liquidity-covenant position.
- Actual UltraMIST and biologics sales, the reported revenue discrepancy, and any effects of the Celularity and Minnetronix disputes on supply and commercialization.
- Financing completed after year-end, potential dilution from outstanding warrants and convertibles, and the share count on a fully diluted basis.
- Remediation of material weaknesses and filing timeliness, as well as the resulting status and liquidity of the OTC market for the common stock.